Personalized vaccine aims to stop lynch syndrome cancers before they start
NCT ID NCT07609901
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase III trial tests whether a vaccine made from a person's own immune cells can prevent cancer in 372 adults with Lynch syndrome, a genetic condition that raises cancer risk. Participants receive either the vaccine or a placebo and are monitored for tumor development. The goal is to see if the vaccine can keep cancer from forming.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYNCH SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Radboudumc
Nijmegen, Gelderland, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a walking routine alter cancer biomarkers? new trial investigates
- Digital assistant aims to close gaps in hereditary cancer care
- Lynch syndrome patients share colonoscopy struggles in new survey
- Swiss study aims to find hidden cancer genes in families
- Could lynch syndrome raise your risk of gum disease?
- New program aims to keep High-Risk cancer gene carriers on track with screenings